title: Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
abstract: In a population-based study, the Nordic Myeloma Study Group found a survival advantage for high-dose melphalan with autologous blood stem-cell support compared to conventional chemotherapy in myeloma patients under 60 yr of age (risk ratio: 1.62; confidence interval [CI] 1.22-2.15; p = 0.001). A study of health-related quality of life (HRQoL) was integrated in the trial, using the EORTC QLQ-C30 questionnaire. Of the 274 patients receiving intensive therapy 221 (81%) were compared to 113 (94%) of 120 patients receiving conventional melphalan-prednisone treatment. Prior to treatment, there were no statistically significant differences in any HRQoL score between the two groups. One month after the start of induction chemotherapy, the patients on intensive treatment had more sleep disturbance than the control patients. At 6 mo, corresponding to a mean of 52 d after high-dose melphalan, the patients on intensive treatment had moderately lower scores for global QoL and role and social functioning and there was also a significantly higher score for appetite loss. At 12 and 24 mo, the HRQoL was similar to that of the control patients. At 36 mo, there was a trend toward less fatigue, pain, nausea, and appetite loss in the intensive-treatment group. Thus, the 18 mo of prolonged survival seem to be associated with a good health-related quality of life. Despite the moderate HRQoL reduction associated with the early intensive chemotherapy phase, this treatment modality must be regarded as an important step forward in the care of multiple myeloma.
authors.affiliation: Department of Hematology, Ullevål University Hospital, Oslo, Norway. nina.gulbrandsen@ioks.uio.no
authors.forename: N
authors.initials: N
authors.lastname: Gulbrandsen
authors.forename: F
authors.initials: F
authors.lastname: Wisløff
authors.forename: L
authors.initials: L
authors.lastname: Brinch
authors.forename: K
authors.initials: K
authors.lastname: Carlson
authors.forename: I M
authors.initials: IM
authors.lastname: Dahl
authors.forename: P
authors.initials: P
authors.lastname: Gimsing
authors.forename: E
authors.initials: E
authors.lastname: Hippe
authors.forename: M
authors.initials: M
authors.lastname: Hjorth
authors.forename: L M
authors.initials: LM
authors.lastname: Knudsen
authors.forename: J
authors.initials: J
authors.lastname: Lamvik
authors.forename: S
authors.initials: S
authors.lastname: Lenhoff
authors.forename: E
authors.initials: E
authors.lastname: Løfvenberg
authors.forename: I
authors.initials: I
authors.lastname: Nesthus
authors.forename: J L
authors.initials: JL
authors.lastname: Nielsen
authors.forename: I
authors.initials: I
authors.lastname: Turesson
authors.forename: J
authors.initials: J
authors.lastname: Westin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001066:Appetite; D005260:Female; D006304:Health Status; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011446:Prospective Studies; D011788:Quality of Life; D012893:Sleep Wake Disorders / Q000139:chemically induced; D012919:Social Behavior; D012944:Social Support; D016019:Survival Analysis
chemical_list: D008558:Melphalan